India has officially ended the over-the-counter sale of cough syrups, introducing a major regulatory change aimed at strengthening medicine safety and preventing future tragedies linked to contaminated pharmaceutical products. Under the new cough syrup prescription requirement, consumers across the country will now need a valid prescription from a registered medical practitioner before purchasing cough syrups from pharmacies.
The move marks one of the most significant drug safety reforms in recent years and comes after repeated concerns surrounding contaminated cough syrups that were allegedly linked to child deaths in India and overseas. The new cough syrup prescription rule follows months of regulatory review and consultation, with the Union Ministry of Health and Family Welfare concluding that tighter controls were necessary to improve oversight of medicine distribution.
Cough syrup prescription rule comes into force
The Ministry of Health and Family Welfare has issued a gazette notification removing the term “syrup” from the list of medicines covered under Schedule K of the Drugs and Cosmetics Act, 1945. The decision effectively ends the exemption that previously allowed pharmacies to sell many syrup-based medicines, including cough syrups, without a doctor’s prescription.
With the removal from Schedule K, pharmacies must now verify a valid prescription before dispensing cough syrups. The over-the-counter ban applies nationwide and is expected to significantly alter how consumers access common cough and cold medications.
According to officials familiar with the process, the government had circulated a draft notification in December 2025 and invited feedback from stakeholders. Since no major objections were raised during the consultation period, authorities proceeded with the final notification in June 2026.
Why the government imposed the over-the-counter ban
The over-the-counter ban has been driven largely by growing concerns over contaminated cough syrups and their impact on public health. In recent years, Indian-manufactured cough syrups have faced intense scrutiny following allegations that contaminated products contributed to the deaths of children both domestically and internationally.
The issue attracted global attention as regulators and public health experts investigated instances of contamination involving toxic substances in pharmaceutical formulations. These incidents raised questions about manufacturing standards, quality control procedures, and regulatory compliance across parts of the pharmaceutical supply chain.
Health authorities have increasingly focused on ensuring that potentially vulnerable medicines are distributed under stricter medical supervision. The cough syrup prescription requirement is therefore being viewed as part of a broader effort to improve accountability and reduce risks associated with improper manufacturing practices.
Contaminated cough syrups triggered safety concerns
One of the most alarming cases emerged last year when at least 22 children, most of them in Rajasthan, reportedly died after consuming contaminated cough syrup. Investigations indicated that the product allegedly contained diethylene glycol, a toxic industrial chemical commonly associated with products such as brake fluid and antifreeze.
Laboratory examinations reportedly found concentrations of diethylene glycol far exceeding the permissible safety limit. Experts have long warned that exposure to excessive amounts of the chemical can result in severe kidney damage, organ failure, and death, particularly among young children.
The controversy intensified calls for stronger oversight and prompted regulators to reassess existing frameworks governing medicine sales and distribution.
CDSCO strengthens regulatory oversight
The Central Drugs Standard Control Organisation has been evaluating additional safeguards aimed at preventing future lapses in pharmaceutical manufacturing and distribution. Regulatory experts believe the cough syrup prescription rule could help create an additional layer of scrutiny by ensuring greater involvement of healthcare professionals in the dispensing process.
Public health specialists note that while prescription requirements alone cannot eliminate manufacturing defects, they can improve patient monitoring and encourage more responsible use of medications. Experts also argue that stricter regulations send a strong signal about the government’s commitment to addressing medicine safety concerns.
The introduction of the cough syrup prescription requirement, combined with ongoing regulatory reforms, is expected to form part of a wider strategy to strengthen India’s pharmaceutical safety framework and restore confidence in the country’s medicine supply chain.
As the over-the-counter ban takes effect nationwide, consumers, healthcare providers, and pharmacies will need to adapt to the new system. The government’s decision reflects growing efforts to prioritize public safety and prevent future incidents involving contaminated cough syrups, a concern that has increasingly shaped India’s healthcare regulatory agenda.